TB DRUG SCREENING:TB ANTIMICROBIAL ACQ & COORD. FACILITY

结核病药物筛查：TB 抗菌药物 ACQ

• 批准号: 6158377
• 负责人: JOHN A SECRIST
• 金额: $ 70.39万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2006-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6158377
• 关键词: AIDS; Mycobacterium tuberculosis; antitubercular agents; biomedical facility; drug screening /evaluation; opportunistic infections; tuberculosis

This contract provides the interface with academic establishments and the private sector for evaluation of new classes of compounds for activity against M. tuberculosis. This acquisition component actively canvases medicinal chemists and pursues chemicals and natural products described in the academic literature and in compounds identified via pharmaceutical company repositories. The contract serves as the central storage repository of agents prior to testing. All compounds are tested under a confidentiality agreement and new compounds will be registered with the existing chemical structure database to avoid duplicative testing. The emphasis for exploration in the current contract will be for compounds to kill quiescent or dormant tubercle bacilli present in the latent phase of disease. The contractor is responsible for supplying biological data to the suppliers and for serving as a central contact for further drug development interactions.

该合同提供了与学术机构和私营部门的接口，以评估新型化合物的抗结核分枝杆菌活性。 该收购部分积极调查药物化学家，并寻求学术文献中描述的化学品和天然产物以及通过制药公司存储库鉴定的化合物。 该合约在测试之前充当代理的中央存储库。 所有化合物均根据保密协议进行测试，新化合物将在现有化学结构数据库中注册，以避免重复测试。 当前合同的探索重点是开发杀死疾病潜伏期静止或休眠结核杆菌的化合物。 承包商负责向供应商提供生物数据，并作为进一步药物开发互动的中心联系人。